• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study.退伍军人丙型肝炎评估与治疗中的种族差异:一项回顾性队列研究。
Am J Public Health. 2008 May;98(5):846-52. doi: 10.2105/AJPH.2007.113225. Epub 2008 Apr 1.
2
Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus.丙型肝炎病毒直接作用抗病毒药物使用中的种族和性别差异
Clin Infect Dis. 2016 Aug 1;63(3):291-9. doi: 10.1093/cid/ciw249. Epub 2016 Apr 30.
3
The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.种族/族裔与丙型肝炎病毒感染直接抗病毒药物疗效之间的关联。
Hepatology. 2017 Feb;65(2):426-438. doi: 10.1002/hep.28901. Epub 2016 Dec 24.
4
Racial Differences in Treatment and Survival among Veterans and Non-Veterans with Stage I NSCLC: An Evaluation of Veterans Affairs and SEER-Medicare Populations.I期非小细胞肺癌退伍军人和非退伍军人在治疗与生存方面的种族差异:对退伍军人事务部和监测、流行病学与最终结果-医疗保险人群的评估。
Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):112-118. doi: 10.1158/1055-9965.EPI-19-0245. Epub 2019 Oct 17.
5
Rate and predictors of treatment prescription for hepatitis C.丙型肝炎治疗处方的比率及预测因素。
Gut. 2007 Mar;56(3):385-9. doi: 10.1136/gut.2006.099150. Epub 2006 Sep 27.
6
Pretreatment assessment and predictors of hepatitis C virus treatment in US veterans coinfected with HIV and hepatitis C virus.美国同时感染艾滋病毒和丙型肝炎病毒的退伍军人的丙型肝炎病毒治疗的预处理评估及预测因素
J Viral Hepat. 2006 Dec;13(12):799-810. doi: 10.1111/j.1365-2893.2006.00751.x.
7
Patient and Facility Correlates of Racial Differences in Viral Control for Black and White Veterans with HIV Infection in the Veterans Administration.患者和医疗机构相关因素对在美退伍军人事务部感染 HIV 的黑人和白人退伍军人病毒控制的种族差异的影响。
AIDS Patient Care STDS. 2018 Mar;32(3):84-91. doi: 10.1089/apc.2017.0213.
8
Viral RNA testing in hepatitis C antibody-positive veterans.丙型肝炎抗体阳性退伍军人的病毒RNA检测
Am J Prev Med. 2009 Mar;36(3):235-8. doi: 10.1016/j.amepre.2008.10.013. Epub 2009 Jan 21.
9
Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort.丙型肝炎治愈与退伍军人事务回顾性队列中肝硬化患者的医疗保健费用降低有关。
Dig Dis Sci. 2018 Jun;63(6):1454-1462. doi: 10.1007/s10620-018-4956-0. Epub 2018 Feb 16.
10
Racial differences in hepatitis C treatment eligibility.种族差异对丙型肝炎治疗资格的影响。
Hepatology. 2011 Jul;54(1):70-8. doi: 10.1002/hep.24358.

引用本文的文献

1
Disparities in the quality of care for chronic hepatitis C among Medicare beneficiaries.医疗保险受益人群慢性丙型肝炎护理质量的差异。
PLoS One. 2022 Mar 10;17(3):e0263913. doi: 10.1371/journal.pone.0263913. eCollection 2022.
2
The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment.卫生公平实施框架:丙型肝炎病毒治疗的建议和初步研究。
Implement Sci. 2019 Mar 12;14(1):26. doi: 10.1186/s13012-019-0861-y.
3
Estimates of state-level chronic hepatitis C virus infection, stratified by race and sex, United States, 2010.2010 年美国按种族和性别分层的州级慢性丙型肝炎病毒感染估计数。
BMC Infect Dis. 2018 May 16;18(1):224. doi: 10.1186/s12879-018-3133-6.
4
Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population.保险人群中丙型肝炎病毒感染直接作用抗病毒药物起始治疗的差异。
Public Health Rep. 2018 Jul/Aug;133(4):452-460. doi: 10.1177/0033354918772059. Epub 2018 May 11.
5
Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience.直接抗病毒药物时代慢性丙型肝炎的治疗障碍:单中心经验
BMJ Open Gastroenterol. 2017 Dec 20;4(1):e000181. doi: 10.1136/bmjgast-2017-000181. eCollection 2017.
6
Assessing Racial Disparities in HCV Infection and Care Outcomes in a Southern Urban Population.评估南方城市人群中 HCV 感染和护理结局的种族差异。
J Racial Ethn Health Disparities. 2018 Oct;5(5):1052-1058. doi: 10.1007/s40615-017-0453-y. Epub 2017 Dec 29.
7
Primary Care and Hepatology Provider-Perceived Barriers to and Facilitators of Hepatitis C Treatment Candidacy and Adherence.初级保健和肝病学提供者所感知的丙型肝炎治疗候选资格及依从性的障碍和促进因素。
Dig Dis Sci. 2017 Aug;62(8):1933-1943. doi: 10.1007/s10620-017-4608-9. Epub 2017 May 18.
8
Racial-Ethnic Disparities in Uptake of New Hepatitis C Drugs in Medicare.医疗保险中新型丙型肝炎药物使用的种族-民族差异。
J Racial Ethn Health Disparities. 2017 Dec;4(6):1147-1158. doi: 10.1007/s40615-016-0320-2. Epub 2016 Dec 7.
9
Limited Fibrosis Progression but Significant Mortality in Patients Ineligible for Interferon-Based Hepatitis C Therapy.在不符合基于干扰素的丙型肝炎治疗条件的患者中,纤维化进展有限但死亡率显著。
J Clin Exp Hepatol. 2016 Jun;6(2):100-8. doi: 10.1016/j.jceh.2016.02.006. Epub 2016 Mar 12.
10
Conceptual framework for outcomes research studies of hepatitis C: an analytical review.丙型肝炎结局研究的概念框架:一项分析性综述
Infect Drug Resist. 2016 May 27;9:101-17. doi: 10.2147/IDR.S99329. eCollection 2016.

本文引用的文献

1
Follow-up for medical care among drug users with hepatitis C.丙型肝炎吸毒者的医疗随访。
Eval Health Prof. 2006 Dec;29(4):355-66. doi: 10.1177/0163278706296003.
2
Rate and predictors of treatment prescription for hepatitis C.丙型肝炎治疗处方的比率及预测因素。
Gut. 2007 Mar;56(3):385-9. doi: 10.1136/gut.2006.099150. Epub 2006 Sep 27.
3
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.聚乙二醇干扰素和利巴韦林治疗非裔美国人和高加索裔美国人1型丙型肝炎患者。
Gastroenterology. 2006 Aug;131(2):470-7. doi: 10.1053/j.gastro.2006.06.008.
4
Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race.对干扰素的整体转录反应是丙型肝炎病毒治疗结果的一个决定因素,并因种族而有所改变。
Hepatology. 2006 Aug;44(2):352-9. doi: 10.1002/hep.21267.
5
Using navigators to improve care of underserved patients: current practices and approaches.利用导航工具改善对服务不足患者的护理:当前的实践与方法。
Cancer. 2005 Aug 15;104(4):848-55. doi: 10.1002/cncr.21214.
6
Fighting unequal treatment: the Robert Wood Johnson Foundation and a quality-improvement approach to disparities.对抗不平等治疗:罗伯特·伍德·约翰逊基金会与解决差异的质量改进方法。
Circulation. 2005 Mar 15;111(10):1208-9. doi: 10.1161/01.CIR.0000157739.93631.EB.
7
Chronic hepatitis C treatment patterns in African American patients: an update.非裔美国患者的慢性丙型肝炎治疗模式:最新情况
Am J Gastroenterol. 2005 Mar;100(3):716-22. doi: 10.1111/j.1572-0241.2005.41321.x.
8
Elevated prevalence of hepatitis C infection in users of United States veterans medical centers.美国退伍军人医疗中心使用者中丙型肝炎感染率升高。
Hepatology. 2005 Jan;41(1):88-96. doi: 10.1002/hep.20502.
9
Differences, disparities, and biases: clarifying racial variations in health care use.差异、差距与偏见:厘清医疗保健使用中的种族差异
Ann Intern Med. 2004 Oct 19;141(8):635-8. doi: 10.7326/0003-4819-141-8-200410190-00011.
10
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.聚乙二醇干扰素α-2a(40kd)联合利巴韦林用于美国黑人慢性丙型肝炎基因1型患者。
Hepatology. 2004 Jun;39(6):1702-8. doi: 10.1002/hep.20212.

退伍军人丙型肝炎评估与治疗中的种族差异:一项回顾性队列研究。

Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study.

作者信息

Rousseau Christine M, Ioannou George N, Todd-Stenberg Jeffrey A, Sloan Kevin L, Larson Meaghan F, Forsberg Christopher W, Dominitz Jason A

机构信息

Northwest Health Services Research and Development Center of Excellence and the Northwest Hepatitis C Resource Center, VA Puget Sound Health Care System, Seattle, WA, USA.

出版信息

Am J Public Health. 2008 May;98(5):846-52. doi: 10.2105/AJPH.2007.113225. Epub 2008 Apr 1.

DOI:10.2105/AJPH.2007.113225
PMID:18382007
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2374801/
Abstract

OBJECTIVES

We examined the association between race and hepatitis C virus (HCV) evaluation and treatment of veterans in the Northwest Network of the Department of Veterans Affairs (VA).

METHODS

In our retrospective cohort study, we used medical records to determine antiviral treatment of 4263 HCV-infected patients from 8 VA medical centers. Secondary outcomes included specialty referrals, laboratory evaluation, viral genotype testing, and liver biopsy. Multiple logistic regression was used to adjust for clinical (measured through laboratory results and International Classification of Diseases, Ninth Revision, codes) and sociodemographic factors.

RESULTS

Blacks were less than half as likely as Whites to receive antiviral treatment (odds ratio [OR]=0.38; 95% confidence interval [CI]=0.23, 0.63). Both had similar odds of referral and liver biopsy. However, Blacks were significantly less likely to have complete laboratory evaluation (OR=0.67; 95% CI=0.52, 0.88) and viral genotype testing (OR=0.68; 95% CI=0.51, 0.90).

CONCLUSIONS

Race is associated with receipt of medical care for various medical conditions. Further investigation is warranted to help understand whether patient preference or provider bias may explain why HCV-infected Blacks were less likely to receive medical care than Whites.

摘要

目的

我们研究了退伍军人事务部(VA)西北网络中种族与丙型肝炎病毒(HCV)评估及退伍军人治疗之间的关联。

方法

在我们的回顾性队列研究中,我们使用医疗记录来确定来自8个VA医疗中心的4263名HCV感染患者的抗病毒治疗情况。次要结果包括专科转诊、实验室评估、病毒基因型检测和肝活检。使用多元逻辑回归来调整临床因素(通过实验室结果和国际疾病分类第九版编码衡量)和社会人口统计学因素。

结果

黑人接受抗病毒治疗的可能性不到白人的一半(优势比[OR]=0.38;95%置信区间[CI]=0.23,0.63)。两者在转诊和肝活检方面的可能性相似。然而,黑人进行完整实验室评估的可能性显著较低(OR=0.67;95%CI=0.52,0.88),进行病毒基因型检测的可能性也显著较低(OR=0.68;95%CI=0.51,0.90)。

结论

种族与各种医疗状况的医疗护理接受情况相关。有必要进行进一步调查,以帮助了解患者偏好或医疗服务提供者的偏见是否可以解释为什么HCV感染的黑人比白人接受医疗护理的可能性更低。